BerGenBio

AGM Information • Apr 12, 2019

BerGenBio ASA: Exercise of share options and increase of share capital

BerGenBio ASA: Exercise of share options and increase of share capital

Bergen, Norway, 12 April 2019.

Exercise of share options and increase of share capital

BerGenBio ASA (the "Company") (OSE: BGBIO) today announces that in order to to fulfil the Company's obligations under its option scheme the Board of Directors has resolved to increase the Company's share capital by NOK 10,000 by issuance of 100,000 new shares. The new shares have been issued to an existing option owner entitled to exercise options in accordance with the Company's option scheme. The subscription price is in accordance with the prevailing options price pursuant to the Company´s option scheme, in average NOK 16.01 per share.

The capital increase is expected to be registered within 7 days, and following the issuance of the new shares, the issued share capital of BerGenBio ASA will be NOK 5,495,144.60 consisting of 54,951,446 shares, each with a par value of NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.